News & Updates

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.

Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

Patients with melanoma of unknown primary (MUP) benefit from novel therapies similarly as those with stage-matched melanoma of known cutaneous primary (cMKP) despite having less favourable baseline prognostic factors, reveals a study.

The performance of a prognostic model with sentinel lymph node (SLN) biopsy status in assessing patient risk for 5-year melanoma-specific death is superior to that of a model with primary tumour staging factors alone for threshold mortality rates ≥30 percent, a study has shown.

Patients with rectal cancer who are monitored using a watch-and-wait approach are more likely to have a good quality of life, whereas those who undergo surgery appear to experience deterioration in quality of life and functional outcome, as reported in a study.